Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effects of semaglutide and liraglutide on urinary albumin-to-creatinine ration (UACR) -A pooled analysis of sustain 6 and leader

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Carotid-femoral pulse wave velocity is a risk marker for complications in persons with type 1 diabetes

    Publikation: KonferencebidragKonferenceabstrakt til konferenceForskning

  2. Mitigating risk of aldosterone in diabetic kidney disease

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Vlado Perkovic
  • Stephen C Bain
  • George L Bakris
  • John B Buse
  • Thomas Idorn
  • Kenneth W Mahaffey
  • Steven P Marso
  • Michael A Nauck
  • Richard E Pratley
  • Søren Rasmussen
  • Peter Rossing
  • Karen Tornøe
  • Bernard Zinman
  • Johannes Mann
Vis graf over relationer
Introduction and Aims UACR is a marker of renal damage and renal disease progression risk; UACR reduction has been shown to correlate with renal protection. This post hoc analysis of pooled data from SUSTAIN 6 and LEADER investigated the effects of glucagon-like peptide-1 (GLP-1) analogues semaglutide and liraglutide vs placebo on UACR. Methods Primary outcome in both trials: major adverse cardiovascular events. Nephropathy events and change in renal biochemistry, including UACR, were secondary outcomes. In this analysis (N=11812), patients were stratified by baseline UACR class (normo-: <30 mg/g, micro-: 30–300 mg/g and macroalbuminuria: >300 mg/g). Risk of categorical changes in UACR (time to persistent: progression to micro- or macroalbuminuria, regression to micro- or normoalbuminuria, 30% reduction) and UACR change from baseline to 2 years were analysed by baseline UACR using a Cox regression model (with treatment as a fixed factor and stratified by study) and a mixed model on log-transformed values, respectively. Results GLP-1 analogues reduced risk of progression to micro- or macroalbuminuria and increased the likelihood of regression in albuminuria category vs placebo. The likelihood of reaching 30% UACR reduction was greater with the GLP-1 analogues vs placebo (p<0.0001 for all UACR subgroups) (Table). UACR increased relatively more from baseline to 2 years for placebo vs GLP-1 analogues for the pooled population and patients with baseline normo-, micro- and macroalbuminuria (24%, 20%, 30% and 21%, respectively). Conclusions This pooled analysis shows beneficial effects on UACR for GLP-1 analogues semaglutide and liraglutide vs placebo irrespective of baseline UACR.
TidsskriftNephrology Dialysis Transplantation
Udgave nummerSuppl 1
Sider (fra-til)205
StatusUdgivet - jun. 2019
BegivenhedERA-EDTA 2019 - Hungexpo, Budapest, Ungarn
Varighed: 13 jun. 201919 jun. 2019


KonferenceERA-EDTA 2019




Budapest, Ungarn

Begivenhed: Konference

ID: 58505201